Lifecore Biomedical Inc. (LFCR)
| Bid | 5.74 |
| Market Cap | 237.33M |
| Revenue (ttm) | 130.31M |
| Net Income (ttm) | -44.65M |
| EPS (ttm) | -1.47 |
| PE Ratio (ttm) | -4.36 |
| Forward PE | -9.77 |
| Analyst | Hold |
| Ask | 6.7 |
| Volume | 169,098 |
| Avg. Volume (20D) | 217,680 |
| Open | 6.31 |
| Previous Close | 6.33 |
| Day's Range | 6.26 - 6.55 |
| 52-Week Range | 3.68 - 7.99 |
| Beta | 0.80 |
About LFCR
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a ...
Analyst Forecast
According to 3 analyst ratings, the average rating for LFCR stock is "Hold." The 12-month stock price forecast is $8, which is an increase of 24.80% from the latest price.
Stock Forecasts
2 weeks ago · seekingalpha.com
Lifecore Biomedical, Inc. (LFCR) Q3 2025 Earnings Call TranscriptLifecore Biomedical, Inc. (NASDAQ:LFCR ) Q3 2025 Earnings Conference Call April 3, 2025 4:30 PM ET Company Participants Stephanie Diaz - Manager, IR Paul Josephs - CEO Ryan Lake - CFO Conference Call ...
